ArticleScientific reports2025
LncRNA MIR210HG promotes the proliferation of colon cancer cells by inhibiting ferroptosis through binding to PCBP1.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of non-coding RNA-regulated ferroptosis in colorectal cancer.Cell death discovery · 2025Review
- The construction and evaluation of a prognostic risk score model for HCC based on MPT-related lncRNAs.Frontiers in oncology · 2025Article
- Sensory neuropeptide CGRP and its co-receptor RAMP1 drive tumour cell growth in gastrointestinal cancers.BMJ oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study aimed to investigate the role of the MIR210 host gene (MIR210HG), a long noncoding RNA (lncRNA), in the proliferation of colon cancer cells and its potential mechanism involving the ferroptosis pathway. We assessed MIR210HG expression in colon cancer cell lines and tissues, and examined the effects of its overexpression and knockdown on cell proliferation. Proteomic analysis was conducted to explore the interaction between MIR210HG and ferroptosis pathway components. The binding of MIR210HG to poly(rC) binding protein 1 (PCBP1) was predicted using catRAPID and confirmed through RNA pull-down and RNA immunoprecipitation (RIP) experiments. MIR210HG was significantly upregulated in colon cancer cells and tissues. Its overexpression promoted, while its knockdown inhibited, colon cancer cell proliferation. MIR210HG was found to be associated with ferroptosis pathway components and to bind to PCBP1, which was experimentally validated. The inhibition of ferroptosis by MIR210HG through PCBP1 binding was confirmed, highlighting its role in promoting cell proliferation. MIR210HG promotes colon cancer cell proliferation by binding to PCBP1 and inhibiting ferroptosis. These findings suggest MIR210HG as a potential therapeutic target for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.